Australasian Dental Practice

Monday, 22 July, 2024

01 Jan 2010 | Australasian Dental Practice

news > Spectrum > Page 48

Vaccine to treat gum disease on the way

Gum disease

CSL Limited, Australia's leading biopharmaceutical company, has today announced that a vaccine to treat severe gum disease is being developed in a new collaboration with Sanofi Pasteur, the world's leading global manufacturer of vaccines.


CSL has signed an agreement with Sanofi Pasteur to fund a program in the Cooperative Research Centre for Oral Health Science based at the University of Melbourne for the further development of a vaccine to prevent and treat peridontitis.

Up to 30% of Australian adults suffer from the disease which has been linked with heart disease, stroke, adverse pregnancy outcomes, dementia and cancer.

Following more than ten years of research, scientists from The University of Melbourne and CSL have identified candidate vaccine antigens for periodontitis.

"Periodontitis is a serious disease and dentists face a major challenge in treating it, because most people will not know they have the disease until it's too late and the infection has progressed to advanced stages," said Professor Eric Reynolds, CEO of the CRC for Oral Health Science and the Head of The University of Melbourne's Dental School.

"Traditional treatment for the disease often involves scaling and cleaning and even surgery in an effort to contain the bacterial infection."

This new vaccine approach targets the 'ring leader' of a group of pathogenic bacteria that cause periodontitis, the bacterium called Porphyromonas gingivalis.

"We are very excited about this novel approach to the disease," Prof. Reynolds said. "It will provide dentists and patients with a specific treatment, which prevents disease progression, rather than managing its symptoms and damaging consequences."

"It has taken over ten years to develop the vaccine to this stage," said Dr Andrew Cuthbertson, CSL's Chief Scientific Officer. "CSL is pleased to advise of an agreement with Sanofi Pasteur to undertake a funded program to develop a vaccine for the treatment of periodontal disease caused by Porphyromonas gingivalis."

The vaccine development program involves identifying the bacterial peptides and proteins that trigger the immune response and using these as the basis of vaccines. The vaccines are being trialled in mouse models of periodontal disease and following a positive response, a vaccine will progress to clinical trials.

Should this program be successful, Sanofi Pasteur has an option to an exclusive worldwide license to commercialise the intellectual property associated with these products.

The Cooperative Research Centre for Oral Health brings together scientists, dentists, population health experts and manufacturers to find new and efficient ways of reducing the burden of oral disease in Australia. The Centre is based at The University of Melbourne and collaborates with institutes and manufacturers from around the world. It is funded by the Federal Government's CRC Program.

Stream the latest dental videos...
VITA ENAMIC Reworking Tutorial

Upcoming Events...

Jul 25 2024
Aug 07 2024
Aug 20 2024
Aug 21 2024
Aug 23 2024
Aug 28 2024
Aug 29 2024

Practical Endodontics Workshop

Sydney, AUSTRALIA

Sep 04 2024
Sep 07 2024
Sep 11 2024
Sep 14 2024
Sep 26 2024
Oct 02 2024
Oct 03 2024
Oct 10 2024
Oct 17 2024

ADOHTA 2024 National Congress

Sydney, AUSTRALIA

Oct 24 2024
Nov 06 2024
Nov 07 2024

Veneers: A Comprehensive Guide

Auckland, NEW ZEALAND

Nov 13 2024
Nov 29 2024
Dec 04 2024
Mar 25 2025

IDS 2025

Cologne, GERMANY

May 08 2025
May 30 2025
Mar 20 2026
Apr 17 2026

IDEM Singapore 2026

Singapore, SINGAPORE